VAY736 Emerging Drug Insight and Market Forecast - 2032

“VAY736 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about VAY736 for lupus nephritis in the seven major markets. A detailed picture of the VAY736 for lupus nephritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the VAY736 for lupus nephritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAY736 market forecast analysis for lupus nephritis in the 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in lupus nephritis.

Drug Summary

Ianalumab (VAY736) is a subcutaneously administered fully human HuCAL antibody that targets BAFF-R and is being investigated by MorphoSys and Novartis for the treatment of autoimmune hepatitis, idiopathic pulmonary fibrosis, SLE, and lupus nephritis. It is an anti-B-cell activating factor (BAFF) receptor fully human monoclonal antibody, engineered for direct ADCC-mediated B-cell depletion.

Currently, the drug is being evaluated in Phase III (NCT05126277) for the treatment of participants with active lupus nephritis.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the VAY736 description, mechanism of action, dosage and administration, research and development activities in lupus nephritis.
• Elaborated details on VAY736 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VAY736 research and development activities in lupus nephritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VAY736.
• The report contains forecasted sales of VAY736 for lupus nephritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for lupus nephritis.
• The report also features the SWOT analysis with analyst views for VAY736 in lupus nephritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VAY736 Analytical Perspective

In-depth VAY736 Market Assessment

This report provides a detailed market assessment of VAY736 for lupus nephritis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data of VAY736.

VAY736 Clinical Assessment

The report provides the clinical trials information of VAY736 for lupus nephritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for lupus nephritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAY736 dominance.
• Other emerging products for lupus nephritis are expected to give tough market competition to VAY736 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAY736 in lupus nephritis.
• Our in-depth analysis of the forecasted sales data of VAY736 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VAY736 in lupus nephritis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of VAY736?
• What is the clinical trial status of the study related to VAY736 in lupus nephritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAY736 development?
• What are the key designations that have been granted to VAY736 for lupus nephritis?
• What is the forecasted market scenario of VAY736 for lupus nephritis?
• What are the forecasted sales of VAY736 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VAY736 for lupus nephritis?
• Which are the late-stage emerging therapies under development for the treatment of lupus nephritis?